Results 141 to 150 of about 12,450 (234)
Shubhra Chaturvedi,1 Sangeeta Lal,2 Prasenjit Sen,3 Anil K Mishra1 1Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, New Delhi, Delhi, 2Department of Physics, B.S.
Chaturvedi S, Lal S, Sen P, Mishra AK
doaj
Two dicarbadodecaborane(12)‐based dual cyclooxygenase‐2/5‐lipoxygenase (COX‐2/5‐LO) inhibitors were 123I‐labeled. Refinement of labeling and formulation conditions and extensive in vitro characterization are presented. Cell uptake studies in COX‐2‐ and 5‐LO‐overexpressing cell lines showed COX‐2‐independent and partly 5‐LO‐dependent uptake.
Jonas Schädlich +11 more
wiley +1 more source
Radiopharmaceutical Production and Quality Control [PDF]
With the development of shorter-lived, organ-specific radiopharmaceuticals, much of the manufacture and quality control of these products have shifted from commercial manufactures to individual nuclear medicine laboratories.
Hirsch, Jerry I.
core +1 more source
The role of IAEA in the Development of Radiopharmaceutical Sciences with Focus on Alpha Emitters [PDF]
Amirreza Jalilian +3 more
openaire +1 more source
Muchtaridi Muchtaridi,1,2 Wiwit Nurhidayah,1 Taufik Muhammad Fakih,1,3 Kento Kannaka,4 Hiroyuki Suzuki,4 Toto Subroto,5 Tomoya Uehara4 1Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang,
Muchtaridi M +6 more
doaj
Radiolabelled choline and FDG PET/CT: two alternatives for the assessment of lymph node metastases in patients with upper urinary tract urothelial carcinoma [PDF]
Evangelista, Laura +3 more
core +1 more source
The use of mass cytometry (CyTOF) to evaluate the cellular uptake of stable radiopharmaceutical surrogates in single cells: a proof-of-concept study. [PDF]
Gómez-Sánchez M +5 more
europepmc +1 more source
Using advanced cell models for targeted radionuclide therapy evaluation: increased efficacy in 3D versus 2D. [PDF]
Klomp MJ +4 more
europepmc +1 more source

